Matches in SemOpenAlex for { <https://semopenalex.org/work/W19449212> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W19449212 endingPage "e15052" @default.
- W19449212 startingPage "e15052" @default.
- W19449212 abstract "e15052 Background: In AIPC, the combination of docetaxel and prednisone has been shown to increase overall survival and progression free survival. Ketoconazole is considered in patients with AIPC to improve symptoms and progression free survival (PFS). Currently, literature evaluating PSA response rates (RR) in patients who receive ketoconazole after docetaxel failure is lacking. Methods: This study evaluated patients with AIPC treated with ketoconazole between January 1, 1999 and September 30, 2009. Patients included in the analysis had failed androgen deprivation therapy and were subsequently initiated on ketoconazole. Nominal data was evaluated with Fisher's Exact Test and continuous data was evaluated with Mann Whitney U or log rank tests. The primary objective of this study was to evaluate PSA response (PSA decline >50% maintained at least 4 weeks) in patients receiving ketoconazole therapy with or without prior docetaxel therapy. Results: A total of 30 patients were included in the analysis. Mean baseline age in the groups with (n=15) and without (n=15) prior docetaxel therapy was 68.8 and 72 years, respectively. More patients in the prior docetaxel group had a performance status of 0 or 1 (80% vs. 47%; p=0.13). Most patients had received prior therapy with an antiandrogen (93.3% and 100%), and the percentage of patients who received antiandrogen withdrawal therapy was 13.3% and 33.3% in prior docetaxel and no prior docetaxel groups, respectively. Median baseline PSA and duration of ketoconazole therapy were similar between groups (109.4 ng/ml vs. 80.4 ng/ml and 5.8 vs. 6.9 months, respectively). PSA response rates were 66.7% in patients with prior docetaxel and 46.7% in patients without prior docetaxel (p=0.46). Median PFS of 7.2 vs. 7.4 months (p=0.85) were similar between groups. Conclusions: Patients receiving ketoconazole who have received prior docetaxel have similar response rates compared to patients who have not received prior docetaxel. No significant financial relationships to disclose." @default.
- W19449212 created "2016-06-24" @default.
- W19449212 creator A5004407611 @default.
- W19449212 creator A5009829916 @default.
- W19449212 creator A5046470867 @default.
- W19449212 creator A5067693233 @default.
- W19449212 creator A5086316849 @default.
- W19449212 date "2010-05-20" @default.
- W19449212 modified "2023-09-27" @default.
- W19449212 title "Response to ketoconazole after failure of docetaxel in patients with advanced androgen-independent prostate cancer (AIPC)." @default.
- W19449212 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.e15052" @default.
- W19449212 hasPublicationYear "2010" @default.
- W19449212 type Work @default.
- W19449212 sameAs 19449212 @default.
- W19449212 citedByCount "0" @default.
- W19449212 crossrefType "journal-article" @default.
- W19449212 hasAuthorship W19449212A5004407611 @default.
- W19449212 hasAuthorship W19449212A5009829916 @default.
- W19449212 hasAuthorship W19449212A5046470867 @default.
- W19449212 hasAuthorship W19449212A5067693233 @default.
- W19449212 hasAuthorship W19449212A5086316849 @default.
- W19449212 hasConcept C121608353 @default.
- W19449212 hasConcept C126322002 @default.
- W19449212 hasConcept C126894567 @default.
- W19449212 hasConcept C143998085 @default.
- W19449212 hasConcept C16005928 @default.
- W19449212 hasConcept C2776694085 @default.
- W19449212 hasConcept C2777899217 @default.
- W19449212 hasConcept C2779322244 @default.
- W19449212 hasConcept C2779548794 @default.
- W19449212 hasConcept C2780192828 @default.
- W19449212 hasConcept C2781064554 @default.
- W19449212 hasConcept C2781190966 @default.
- W19449212 hasConcept C71924100 @default.
- W19449212 hasConceptScore W19449212C121608353 @default.
- W19449212 hasConceptScore W19449212C126322002 @default.
- W19449212 hasConceptScore W19449212C126894567 @default.
- W19449212 hasConceptScore W19449212C143998085 @default.
- W19449212 hasConceptScore W19449212C16005928 @default.
- W19449212 hasConceptScore W19449212C2776694085 @default.
- W19449212 hasConceptScore W19449212C2777899217 @default.
- W19449212 hasConceptScore W19449212C2779322244 @default.
- W19449212 hasConceptScore W19449212C2779548794 @default.
- W19449212 hasConceptScore W19449212C2780192828 @default.
- W19449212 hasConceptScore W19449212C2781064554 @default.
- W19449212 hasConceptScore W19449212C2781190966 @default.
- W19449212 hasConceptScore W19449212C71924100 @default.
- W19449212 hasIssue "15_suppl" @default.
- W19449212 hasLocation W194492121 @default.
- W19449212 hasOpenAccess W19449212 @default.
- W19449212 hasPrimaryLocation W194492121 @default.
- W19449212 hasRelatedWork W2299690226 @default.
- W19449212 hasRelatedWork W2501991984 @default.
- W19449212 hasRelatedWork W2506736007 @default.
- W19449212 hasRelatedWork W2776594178 @default.
- W19449212 hasRelatedWork W2907060458 @default.
- W19449212 hasRelatedWork W2912565296 @default.
- W19449212 hasRelatedWork W3111556708 @default.
- W19449212 hasRelatedWork W3204029969 @default.
- W19449212 hasRelatedWork W4226040508 @default.
- W19449212 hasRelatedWork W4290973876 @default.
- W19449212 hasVolume "28" @default.
- W19449212 isParatext "false" @default.
- W19449212 isRetracted "false" @default.
- W19449212 magId "19449212" @default.
- W19449212 workType "article" @default.